IN2014CN03333A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03333A
IN2014CN03333A IN3333CHN2014A IN2014CN03333A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A IN 3333CHN2014 A IN3333CHN2014 A IN 3333CHN2014A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A
Authority
IN
India
Prior art keywords
shk
potassium channel
inhibiting agent
modified
obesity
Prior art date
Application number
Other languages
English (en)
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of IN2014CN03333A publication Critical patent/IN2014CN03333A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3333CHN2014 2011-10-03 2012-10-02 IN2014CN03333A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
IN2014CN03333A true IN2014CN03333A (enrdf_load_stackoverflow) 2015-07-03

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3333CHN2014 IN2014CN03333A (enrdf_load_stackoverflow) 2011-10-03 2012-10-02

Country Status (16)

Country Link
US (2) US20150072940A1 (enrdf_load_stackoverflow)
EP (1) EP2763702A4 (enrdf_load_stackoverflow)
JP (1) JP2014531469A (enrdf_load_stackoverflow)
KR (1) KR20140108518A (enrdf_load_stackoverflow)
CN (1) CN103987408A (enrdf_load_stackoverflow)
AU (1) AU2012318736A1 (enrdf_load_stackoverflow)
BR (1) BR112014008065A2 (enrdf_load_stackoverflow)
CA (1) CA2850357A1 (enrdf_load_stackoverflow)
HK (1) HK1201048A1 (enrdf_load_stackoverflow)
IL (1) IL231873A0 (enrdf_load_stackoverflow)
IN (1) IN2014CN03333A (enrdf_load_stackoverflow)
MX (1) MX2014004029A (enrdf_load_stackoverflow)
RU (1) RU2014117558A (enrdf_load_stackoverflow)
SG (1) SG11201401193XA (enrdf_load_stackoverflow)
TW (1) TW201321403A (enrdf_load_stackoverflow)
WO (1) WO2013052507A1 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004074A (es) * 2004-10-07 2007-08-14 Univ California Analogos de toxina shk y sus usos en inhibicion selectiva de canales de potasio kv1.3.
CN103687608B (zh) * 2011-06-06 2018-06-26 奇尼塔一有限责任公司 基于shk的医药组合物以及其制备和使用方法
SG11201401193XA (en) 2011-10-03 2014-05-29 Univ California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
TWI701249B (zh) 2015-03-13 2020-08-11 德商4Sc製藥公司 Kv1.3抑制劑及其醫學應用
TWI698438B (zh) 2015-03-13 2020-07-11 德商4Sc製藥公司 Kv1.3抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
AU5369798A (en) * 1996-11-27 1998-06-22 Bachem Bioscience, Inc. Shk toxin compositions and methods of use
AU8052798A (en) * 1997-09-17 1999-04-05 Bachem Bioscience, Inc. Polypeptide compositions that inhibit potassium channel activity and uses herefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
MX2007004074A (es) 2004-10-07 2007-08-14 Univ California Analogos de toxina shk y sus usos en inhibicion selectiva de canales de potasio kv1.3.
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
MX2008002193A (es) * 2005-08-17 2008-03-25 Solvay Pharm Gmbh Metodos para usar compuestos inhibidores del canal de potasio.
AR074558A1 (es) * 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
SG11201401193XA (en) 2011-10-03 2014-05-29 Univ California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Also Published As

Publication number Publication date
MX2014004029A (es) 2014-08-01
EP2763702A1 (en) 2014-08-13
JP2014531469A (ja) 2014-11-27
US9878006B2 (en) 2018-01-30
TW201321403A (zh) 2013-06-01
CN103987408A (zh) 2014-08-13
RU2014117558A (ru) 2015-11-10
BR112014008065A2 (pt) 2019-09-24
IL231873A0 (en) 2014-05-28
WO2013052507A1 (en) 2013-04-11
US20150072940A1 (en) 2015-03-12
SG11201401193XA (en) 2014-05-29
KR20140108518A (ko) 2014-09-11
EP2763702A4 (en) 2015-04-15
CA2850357A1 (en) 2013-04-11
AU2012318736A1 (en) 2014-05-22
US20170095530A1 (en) 2017-04-06
HK1201048A1 (en) 2015-08-21

Similar Documents

Publication Publication Date Title
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
IN2014CN03333A (enrdf_load_stackoverflow)
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX364220B (es) Metodos de tratamientos de fibrosis.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MX374612B (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
MX364643B (es) USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
UA61499U (en) massage mat
UA63764U (ru) Применение экстракта из листьев сныти обыкновенной в качестве лечебно-профилактического средства с гепатопротекторным действием